Theseus Pharmaceuticals price target lowered to $7 from $24 at Wedbush

Wedbush analyst David Nierengarten lowered the firm’s price target on Theseus Pharmaceuticals to $7 from $24 and keeps an Outperform rating on the shares. Theseus will discontinue its THE-630 GIST program and prioritize development of THE-349, its pan-EGFR candidate for the treatment of EGFR+ NSCLC, the analyst tells investors in a research note.